These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38523897)

  • 1. Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study.
    López-Abad A; Ramírez Backhaus M; Server Gómez G; Cao Avellaneda E; Moreno Alarcón C; López Cubillana P; Yago Giménez P; de Pablos Rodríguez P; Juan Fita MJ; Climent Durán MÁ; Guardiola Ruiz I; Vidal Crespo N; Artés Artés M; Montoya Chinchilla R; Moreno Avilés J; Guzmán Martínez-Valls PL; López González PÁ
    Prostate Int; 2024 Mar; 12(1):20-26. PubMed ID: 38523897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world.
    Lu Y; Jiang J; Yang G; Ding H; Zheng Q; Ji L; Wang Y; Dong Z; Zhai Z; Tian J; Zhang Y; Wang J; Yang L; Wang Z
    Front Oncol; 2024; 14():1324181. PubMed ID: 38699643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
    Chowdhury S; Bjartell A; Agarwal N; Chung BH; Given RW; Pereira de Santana Gomes AJ; Merseburger AS; Özgüroğlu M; Juárez Soto Á; Uemura H; Ye D; Brookman-May SD; Londhe A; Bhaumik A; Mundle SD; Larsen JS; McCarthy SA; Chi KN
    Ann Oncol; 2023 May; 34(5):477-485. PubMed ID: 36858151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy.
    Merseburger AS; Agarwal N; Bjartell A; Uemura H; Soto AJ; Bhaumik A; Böhm J; Tran N; Krochmann N; Nematian-Samani M; Mundle SD; Brookman-May SD; Lopez-Gitlitz A; McCarthy SA; Chi K; Chowdhury S
    BJU Int; 2024 Jun; ():. PubMed ID: 38940282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients.
    Sánchez JC; Picola N; Rodriguez-Vida A; Costa M; Castañeda DM; Márquez MP; Rodriguez JM; Gaya JM; Bravo A; Buisan O; Servian P; Suarez JF; Felip MM; Caparrós MJR; Asensio AA; Vilaseca A
    Cancer Med; 2023 Dec; 12(24):21969-21977. PubMed ID: 38063364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy for high-volume
    Jian T; Zhan Y; Yu Y; Yu K; Hu R; Wang J; Lu J
    Front Pharmacol; 2023; 14():1148021. PubMed ID: 37153773
    [No Abstract]   [Full Text] [Related]  

  • 7. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
    Saad F; Small EJ; Feng FY; Graff JN; Olmos D; Hadaschik BA; Oudard S; Londhe A; Bhaumik A; Lopez-Gitlitz A; Thomas S; Mundle SD; Chowdhury S; Smith MR
    Eur Urol; 2022 Feb; 81(2):184-192. PubMed ID: 34916086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
    Lambert E; Hollebosch S; van Praet C; Van Bruwaene S; Duck L; De Roock W; van Wambeke S; Ghysel C; Ameye F; Schatteman P; Vandenbroucke F; Sautois B; Baekelandt F; Ost D; Fransis K; Filleul B; Remondo C; Wynendaele W; Bamelis B; Logghe P; Vergauwe E; Denies E; Joniau S; Lumen N
    Acta Clin Belg; 2022 Dec; 77(6):897-905. PubMed ID: 34789066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do Indian men have similar oncological outcomes with abiraterone plus androgen deprivation therapy in the setting of metastatic hormone-sensitive prostate cancer? A prospective observational study.
    Mandal S; Tarigopula V; Kumaraswamy S; Das MK; Tripathy S; Barik K; Nayak P
    Indian J Urol; 2024; 40(3):174-178. PubMed ID: 39100617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis.
    Kamijima T; Yaegashi H; Mizokami A; Nakajima K; Matsuyama H; Ichikawa T; Nishimoto K; Takahashi S; Shiina H; Horikoshi H; Hashine K; Sugiyama Y; Miyao T; Kamiyama M; Harada K; Ito A; Enokida H
    Anticancer Res; 2022 Jun; 42(6):3099-3108. PubMed ID: 35641302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer.
    Ueda T; Shiraishi T; Miyashita M; Kayukawa N; Gabata Y; Sako S; Ogura R; Fujihara A; Okihara K; Ukimura O
    Sci Rep; 2024 Jan; 14(1):705. PubMed ID: 38184704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
    Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
    Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
    Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
    Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)].
    Merseburger AS; Suttmann H
    Aktuelle Urol; 2021 Apr; 52(2):155-160. PubMed ID: 33113571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Factors in Hormone-sensitive Prostate Cancer Patients Treated With Combined Androgen Blockade: A Consecutive 15-year Study at a Single Japanese Institute.
    Miyazawa Y; Sekine Y; Arai S; Oka D; Nakayama H; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
    In Vivo; 2021; 35(1):373-384. PubMed ID: 33402486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world retrospective study of prostate-specific antigen and safety assessment with darolutamide plus androgen deprivation therapy for metastasis hormone-sensitive prostate cancer.
    Liu J; Wang S; Yang Y; Wang S; Campobasso D; Tan YG; Gao Q; Yang L; Cao Y; Ji Y; Du P; Zhang B
    Transl Androl Urol; 2024 Mar; 13(3):433-441. PubMed ID: 38590967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors.
    Suzuki K; Shiraishi Y; Furukawa J; Okamura Y; Bando Y; Hara T; Okada K; Terakawa T; Hyodo Y; Chiba K; Teishima J; Nakano Y; Miyake H
    Clin Genitourin Cancer; 2024 Oct; 22(5):102140. PubMed ID: 39018723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
    Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
    Chowdhury S; Bjartell A; Agarwal N; Chung BH; Given RW; Pereira de Santana Gomes AJ; Merseburger AS; Özgüroğlu M; Soto ÁJ; Uemura H; Ye DW; Brookman-May SD; Londhe A; Bhaumik A; Mundle SD; Larsen JS; McCarthy SA; Chi KN
    Future Oncol; 2024 Mar; 20(10):563-578. PubMed ID: 38126311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.
    Parikh M; Tangen C; Hussain MHA; Gupta S; Callis S; Jo Y; Harzstark A; Paller CJ; George S; Zibelman MR; Cheng HH; Maughan BL; Zhang J; Pachynski RK; Bryce AH; Lin DW; Quinn DI; Lerner SP; Thompson IM; Dorff TB; Lara PN; Agarwal N
    Eur Urol Oncol; 2024 Oct; 7(5):1097-1104. PubMed ID: 38523017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.